Mirvetuximab soravtansine-gynx (Elahere)
Dilution requiredFull monograph review pending
U.S. label preparation
Elahere · Dilution required
- Preparation
- Use only 5% dextrose and target 1-2 mg/mL. The product is incompatible with 0.9% sodium chloride.
- Administration and handling
- Use the labeled infusion set and rate escalation. Follow ocular premedication and monitoring instructions.
Product and source details
ImmunoGen, Inc. · BLA761310
Product NDC: 72903-853
SPL effective 2025-07-14 | SPL version 14. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.